NCNbio srl

E' alle sue battute conclusive il "Forum nazionale sulla medicina di precisione" di Palermo organizzato da Fondazione Heal (ente che riconosce fra i suoi fondatori l'Università degli studi di Palermo) sotto l'egida del Ministero Istruzione, Universita' e Ricerca. Il CEO di NCNbio srl MariaLuisa Nolli è presente in qualità di membro dello Steering Committee Progetto Heal Italia coordinato da Massimo Dominici. Come ha sottolineato il Rettore massimo midiri, l'evento ha rappresentato un ulteriore passo avanti nell’ambizioso percorso intrapreso da Heal Italia "per stimolare un dibattito di alto profilo, al livello nazionale ma anche europeo ed extraeuropeo, sul cambio epocale che la Sanità può intraprendere grazie alla ricerca nel campo della medicina personalizzata e di precisione". Il Forum è stata una straordinaria occasione di confronto con i rappresentanti delle istituzioni e i principali protagonisti dei settori scientifici e tecnologici coinvolti in questa trasformazione destinata a rendere il network della ricerca traslazionale italiana sempre più competitivo e ad introdurre la medicina di precisione nel sistema sanitario nazionale. European Commission Italia Domani Regione Siciliana Giorgio Stassi #medicinapersonalizzata #medicinadiprecisione #ricercatraslazionale

Approximately 300 million people in the world live with one of the 9,000 currently recognized rare diseases, an area where the one-size-fits-all solutions do not work.   As a manufacturer of rare diseases medicines, you need highly personalized secondary packaging services. Let us support your commitment in improving access to care. CIT Pharma meets all your needs in terms of: 🔎 Ability to handle micro lots 🌎 Global range of authorizations ⏱️ Challenging lead times 🤸♂️ Volume and market flexibility 🎯 Ability to work according to direct-to-patient end-to-end supply model.   🔒 Among our recent achievements… We recently helped a well-known pharma company to manage the launch of a rare disease product in the US, acting in a very short time and playing an essential role in assuring demanding lead times and strict controls. Results beyond expectations convinced our client to double up on their orders.   💥 Ready to enhance your supply chain in rare diseases landscape with a game-changer solutions? Explore our services.   Contact us: 🖊️ e-mail at: federico.casaglia@citppharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma

Approximately 300 million people in the world live with one of the 9,000 currently recognized rare diseases, an area where the one-size-fits-all solutions do not work.   As a manufacturer of rare diseases medicines, you need highly personalized secondary packaging services. Let us support your commitment in improving access to care. CIT Pharma meets all your needs in terms of: 🔎 Ability to handle micro lots 🌎 Global range of authorizations ⏱️ Challenging lead times 🤸♂️ Volume and market flexibility 🎯 Ability to work according to direct-to-patient end-to-end supply model.   🔒 Among our recent achievements… We recently helped a well-known pharma company to manage the launch of a rare disease product in the US, acting in a very short time and playing an essential role in assuring demanding lead times and strict controls. Results beyond expectations convinced our client to double up on their orders.   💥 Ready to enhance your supply chain in rare diseases landscape with a game-changer solutions? Explore our services.   Contact us: 🖊️ e-mail at: federico.casaglia@citppharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma

Alla terza edizione il convegno annuale di #NOTA si conferma un appuntamento importante della rete di #CellFactories impegnate nello sviluppo di #ATMP. L’obiettivo del networking tra le officine dall’idea di Massimiliano Petrini è stato fin dall’inizio molto ambizioso considerando il diverso livello di sviluppo e sostenibilità delle stesse, ma la costanza e chiarezza di intenti sta dando i suoi frutti preparandole all’interazione con l industria, passo necessario per la loro implementazione futura.

BIO-Europe Spring 2025 "Connecting the global biopharma community" has officially begun in Milan. On March 18, Director General of Assobiotec Marica Nobile, PhD will moderate the Panel discussion about Ecosystem innovation featuring Luigi Naldini - San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Matteo G Della Porta - Humanitas Research Hospital, Marco Baccanti - FITT - Foundation for Innovation, Technology and Transfer of Knowledge and Marco Gorini - AstraZeneca. Here the agenda of Day 2: https://lnkd.in/exye3ES4 Register to join the event: https://lnkd.in/dJMgfaaS #BIOEuropeSpring Informa Connect YesMilano Convention Bureau #consulenzabiotech #consulenzaterapieavanzate #atmp #terapieavanzate

ClinOpsHub & NCNbio srl presentano: "𝗟𝗮 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮 𝗱𝗲𝗹 𝗙𝘂𝘁𝘂𝗿𝗼: 𝗘𝘀𝗽𝗹𝗼𝗿𝗮𝗻𝗱𝗼 𝗹𝗲 𝗧𝗲𝗿𝗮𝗽𝗶𝗲 𝗔𝘃𝗮𝗻𝘇𝗮𝘁𝗲" Un evento esclusivo per esplorare l’universo delle terapie avanzate, dalle terapie geniche ai medicinali di ingegneria tessutale, e capire come stanno trasformando la ricerca clinica e la medicina rigenerativa. 📅 𝗤𝘂𝗮𝗻𝗱𝗼? Giovedì 𝟭𝟱 𝗺𝗮𝗴𝗴𝗶𝗼 𝟮𝟬𝟮𝟱, ore 𝟬𝟵:𝟬𝟬 - 𝟭𝟲:𝟯𝟬 📍 𝗗𝗼𝘃𝗲? Azienda Ospedaliera Universitaria Meyer, Firenze 🎤 𝗥𝗲𝗹𝗮𝘁𝗿𝗶𝗰𝗲: Dott.ssa MariaLuisa Nolli 𝗣𝗲𝗿𝗰𝗵é 𝗽𝗮𝗿𝘁𝗲𝗰𝗶𝗽𝗮𝗿𝗲? Scoprirai le ultime innovazioni nelle terapie cellulari e geniche Approfondirai le potenzialità della medicina rigenerativa Avrai l’opportunità di confrontarti con esperti del settore 𝗦𝗰𝗼𝗻𝘁𝗼 𝗱𝗶 𝟭𝟬𝟬€ 𝗱𝗶𝘀𝗽𝗼𝗻𝗶𝗯𝗶𝗹𝗲 𝗮𝗻𝗰𝗼𝗿𝗮 𝗽𝗲𝗿 𝗽𝗼𝗰𝗼! Non perdere l’occasione! 📩 Per info e iscrizioni: scrivi a corsi@formazionenelfarmaceutico.com #MedicinaDelFuturo #TerapieAvanzate #FormazioneMedica #RicercaClinica #atmp #Biotecnologie #CelluleStaminali Monica Torriani

Il 27-28 marzo 2025, presso l'Università degli Studi di Torino - Centro di Biotecnologie Molecolari, si terrà il Terzo #NOTAAnnualMeeting, un’occasione di confronto per tutti gli stakeholder impegnati nel settore delle #terapieavanzate. MariaLuisa Nolli, CEO di NCNbio srl, modererà insieme a Simona Frigerio la Sessione di venerdì 28 marzo dedicata alle "Strategie innovative per il QC e l'integrità dei dati", che ospita gli interventi di: Simona Guidi (ProPharma), Maria Carmela Latella (Holostem S.r.l.), Silvia Carloni (IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl), Luca Bravi (AGC Biologics), Marco Berettoni (Ospedale Pediatrico Bambino Gesù). La partecipazione al meeting è gratuita. E’ possibile iscriversi compilando il modulo on-line disponibile al seguente link: https://lnkd.in/dGiyvd2J  Per informazioni contattare: segreteria@nota-aps.org Massimiliano Petrini Stefano Iacovelli Laura Ridolfi Sara Pignatta Monica Gunetti Laura Fiammenghi Maurizio Gelati Franco Bambi Luciano Castiello Giuseppe Astori #qualitycontrol #consulenzaterapieavanzate #consulenzabiotech #atmp

On March 5, our CEO MariaLuisa Nolli was among the top experts in #advancedtherapies gathered by Healthcare and Life Sciences Club - POLIMI Graduate School of Management to discuss their promises and challenges together with Silvia Gregori and Paola Taroni. In her speech, Maria Luisa Nolli highlighted the new challenges brought by #atmps in terms of #manufacturing complexity, #regulatoryframework and #scalingup in order to promptly bring these innovative solutions to every #patient in need. A heartfelt thank you to the other speakers and to everyone who joined the discussion. Silvia Ceragioli Elena Sambugaro MSc, EMBA Gabriele Saccardo Matteo Bruno, EMBA Michela Cristofolini Giorgio Di Dato Alberto Redaelli Emanuele Lettieri Paolo Locatelli Natascia Colantoni Giorgia Di Massimo POLIMI Graduate School of Management

ClinOpsHub & NCNbio srl presentano: "𝗟𝗮 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮 𝗱𝗲𝗹 𝗙𝘂𝘁𝘂𝗿𝗼: 𝗘𝘀𝗽𝗹𝗼𝗿𝗮𝗻𝗱𝗼 𝗹𝗲 𝗧𝗲𝗿𝗮𝗽𝗶𝗲 𝗔𝘃𝗮𝗻𝘇𝗮𝘁𝗲" Un evento esclusivo per approfondire il mondo delle 𝘁𝗲𝗿𝗮𝗽𝗶𝗲 𝗮𝘃𝗮𝗻𝘇𝗮𝘁𝗲, dalle 𝘁𝗲𝗿𝗮𝗽𝗶𝗲 𝗴𝗲𝗻𝗶𝗰𝗵𝗲 ai 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹𝗶 𝗱𝗶 𝗶𝗻𝗴𝗲𝗴𝗻𝗲𝗿𝗶𝗮 𝘁𝗲𝘀𝘀𝘂𝘁𝗮𝗹𝗲, e scoprire come stanno rivoluzionando la ricerca clinica. 📅 𝗤𝘂𝗮𝗻𝗱𝗼? Giovedì 𝟭𝟱 𝗺𝗮𝗴𝗴𝗶𝗼 𝟮𝟬𝟮𝟱, ore 𝟬𝟵:𝟬𝟬 - 𝟭𝟲:𝟯𝟬 📍 𝗗𝗼𝘃𝗲? Azienda Ospedaliera Universitaria Meyer, Firenze 🎤 𝗥𝗲𝗹𝗮𝘁𝗿𝗶𝗰𝗲: Dott.ssa MariaLuisa Nolli 𝗣𝗲𝗿𝗰𝗵é 𝗽𝗮𝗿𝘁𝗲𝗰𝗶𝗽𝗮𝗿𝗲? - Approfondirai le nuove frontiere della medicina rigenerativa - Conoscerai gli ultimi sviluppi sulle terapie cellulari e geniche - Un’opportunità unica per aggiornarti con esperti del settore 𝗦𝗰𝗼𝗻𝘁𝗼 𝗱𝗶 𝟭𝟬𝟬€ 𝗱𝗶𝘀𝗽𝗼𝗻𝗶𝗯𝗶𝗹𝗲 𝗮𝗻𝗰𝗼𝗿𝗮 𝗽𝗲𝗿 𝗽𝗼𝗰𝗼! Non perdere l’occasione! 📩 Per info e iscrizioni: scrivi a corsi@formazionenelfarmaceutico.com #MedicinaDelFuturo #TerapieAvanzate #FormazioneMedica #RicercaClinica #atmp #Biotecnologie #CelluleStaminali Stefano Lagravinese

🌍 Revolutionizing Medicine, One Cell at a Time On March 5, we gathered top experts in #AdvancedTherapies to discuss their promises and challenges. The takeaway? Medicine is shifting from “one-size-fits-all” to personalized living drugs to treat diseases at their root. 🔬 MariaLuisa Nolli highlighted the new challenges brought by #ATMPs (Advanced Therapy Medicinal Products): ➡️ #Manufacturing complexity: Given the high variability of biological material, ensuring rigorous #quality control is essential to guaranteeing safety and reproducibility: the product is the process. ➡️ #Regulatory framework must adapt to the complexity of ATMPs. Conditional approvals are one approach regulators have introduced to accelerate access while maintaining safety. ➡️ #Scaling up access: Costs remain a barrier to accessibility and investments. As innovative approaches improve efficiency, these therapies will move from niche applications to becoming a commodity in the future. 🧬 Silvia Gregori walked us through the story of excellent research at San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), showcasing how innovation is shaping the future of #genetherapy: 🔹 #Platform approach: once a product is validated for one disease, data and process can be pivoted for others, reducing development time and costs. 🔹 #Genomeediting is enabling safer and more precise therapies. With tools like CRISPR-CAS9 and base editing, we can now reduce risks of off-target effects. 🔹 Beyond #rarediseases, #celltherapies show promise for #autoimmune disorders and organ #transplantation, paving the way for broader applications. 🏥 Paola Taroni provided a deep dive into the challenges of delivering these therapies to patients: ✈️ The #supplychain is delicate, requiring rapid transport, specialized centers, and a strict control of the patient-product identity chain 🦾 #Research #innovation, #automation, and stronger collaboration across industry, academia, and #healthcare systems are required to bring advanced therapies to more patients. 💰 The #investment dilemma: Right now, ATMPs remain an unreturned investment for companies. Despite this, there is a strong commitment to patients and a belief that these therapies will become the standard of care. A #value-based #pricing and #procurement approach will also be critical to ensuring sustainability. 🚀 ATMPs require a multi-perspective approach to tackle these challenges. What do you see as the biggest risks and opportunities in their value chain? Let’s #discuss in the comments! A huge thank you to our speakers and to everyone who joined the discussion! 🚀 Silvia Silvia Elena Elena Gabriele Matteo Michela Giorgio Alberto Redaelli Emanuele Lettieri Paolo Locatelli Natascia Colantoni Giorgia Di Massimo POLIMI Graduate School of Management